Yiqun Hu

ORCID: 0000-0001-8404-3697
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Sexual function and dysfunction studies
  • Genital Health and Disease
  • Hormonal and reproductive studies
  • Gastrointestinal motility and disorders
  • Gastroesophageal reflux and treatments
  • Sexual Differentiation and Disorders
  • Intestinal and Peritoneal Adhesions
  • Glaucoma and retinal disorders
  • Retinal Diseases and Treatments
  • Pain Management and Opioid Use
  • Pharmacological Effects and Toxicity Studies
  • Insect and Pesticide Research
  • Cancer Treatment and Pharmacology
  • Pharmacology and Obesity Treatment
  • Retinal and Macular Surgery
  • Pelvic floor disorders treatments
  • Dupuytren's Contracture and Treatments
  • Forensic Toxicology and Drug Analysis
  • Psoriasis: Treatment and Pathogenesis
  • Urinary Bladder and Prostate Research
  • Statistics Education and Methodologies
  • Sexual Assault and Victimization Studies
  • Hypothalamic control of reproductive hormones
  • Nutritional Studies and Diet
  • Neuroblastoma Research and Treatments

Nanjing University of Chinese Medicine
2025

Guangzhou University of Chinese Medicine
2024

Jinan University
2024

Endo Pharmaceuticals (United States)
2020-2023

Zhongshan Hospital of Xiamen University
2017-2021

AstraZeneca (United States)
2016-2019

Sun Yat-sen University
2009

Zhongshan Ophthalmic Center, Sun Yat-sen University
2008

Peking Union Medical College Hospital
2004

Chinese Academy of Medical Sciences & Peking Union Medical College
2004

Recent advances in natural language processing have leveraged instruction tuning to enhance Large Language Models (LLMs) for table-related tasks. However, previous works train different base models with training data, lacking an apples-to-apples comparison across the result table LLMs. To address this, we fine-tune from Mistral, OLMo, and Phi families on existing public datasets. Our replication achieves performance par or surpassing LLMs, establishing new state-of-the-art Hitab, a...

10.48550/arxiv.2501.14717 preprint EN arXiv (Cornell University) 2025-01-24

No AccessJournal of UrologyAdult Urology1 Jun 2020Long-Term Safety and Curvature Deformity Characterization in Patients Previously Treated with Collagenase clostridium Histolyticum for Peyronie's DiseaseThis article is commented on by the following:Editorial Comment Irwin Goldstein, Larry I. Lipshultz, Michael McLane, Yiqun Hu, Qinfang Xiang, Genzhou Liu, Saji Vijayan, Martin K. Gelbard GoldsteinIrwin Goldstein *Correspondence: Alvarado Hospital, 5555 Reservoir Drive, Suite 300, San Diego,...

10.1097/ju.0000000000000743 article EN The Journal of Urology 2020-01-10

The Aveed Risk Evaluation and Mitigation Strategy program was instituted because of potential risk pulmonary oil microembolism (POME) and/or anaphylaxis after intramuscular injection (testosterone undecanoate), indicated for treatment adult male patients with congenital or acquired primary hypogonadism hypogonadotropic hypogonadism.To analyze the reporting rate POME associated testosterone undecanoate administration (750 mg/3 mL) during postmarketing surveillance.The Endo Pharmaceuticals Inc...

10.1016/j.esxm.2020.01.009 article EN cc-by-nc-nd Sexual Medicine 2020-03-14

This analysis of patient-health care provider discussions opioid-induced constipation (OIC) evaluated the dynamics interactions, identified communication gaps, and assessed functional burden on patients' lives.Retrospective a Health Insurance Portability Accountability Act-compliant database >120,000 patient-provider conversations.Outpatient offices in United States.Conversations between providers patients prescribed opioids that occurred States (January 2014-May 2016) included discussion...

10.1093/pm/pny151 article EN Pain Medicine 2018-07-25

Objectives: To determine patient preference for treating opioid-induced constipation (OIC) using naloxegol or polyethylene glycol (PEG) 3350 in patients receiving opioids noncancer pain. Methods: This crossover study included two 2-week active treatment periods, each preceded by a 1-week washout period (NCT03060512). Individuals with baseline Bowel Function Index scores ≥30 were randomized to 1 of 2 sequences (naloxegol/PEG PEG 3350/naloxegol). Patient (primary end point) was measured at the...

10.14309/ajg.0000000000000229 article EN cc-by The American Journal of Gastroenterology 2019-05-03

Purpose: This study aimed to investigate the possible relationship between retinal vascular abnormalities and amblyopia by analyzing structures of fundus images. Methods: In this observational study, images were collected from 36 patients with unilateral amblyopia, 33 bilateral healthy control volunteers. We developed a customized training algorithm based on U-Net digitalize vasculature in quantify density (area fractal dimension), skeleton length, number bifurcation points. For statistical...

10.1167/tvst.13.5.21 article EN cc-by-nc-nd Translational Vision Science & Technology 2024-05-23

Abstract Introduction Treatments for Peyronie's disease (PD) include surgical management and collagenase clostridium histolyticum (CCH). Aims To evaluate PD treatment trends after CCH approval compare clinical outcomes in CCH- surgery-treated cohorts. Methods Patients newly diagnosed with between January 2011 December 2017 were identified a U.S. claims database. Cohorts initiating or surgery 2014 June included. continuously enrolled ≥6 months before ≥12 index date. Post-treatment penile...

10.1016/j.esxm.2021.100321 article EN cc-by Sexual Medicine 2021-03-05

Background & Objective: Percutaneous endoscopic gastrostomy (PEG) is a procedure to provide enteral nutrition for critically ill patients. It commonly used in clinical practice; however, the widespread use of PEG controversial. Our objective was evaluate therapeutic effect nutritional support by these patients.Methods: A total 64 patients including 41 males and 23 females (aged 23-84) were identified Acute Physiology Chronic Health Evaluation (APACHE) II scoring system during September 2004...

10.12669/pjms.331.11627 article EN cc-by Pakistan Journal of Medical Sciences 2017-02-06

Objective: Efficacy and safety of naloxegol, a peripherally acting μ-opioid receptor antagonist that significantly reduces opioid-induced constipation (OIC), were assessed for patient subgroups defined post hoc by baseline maintenance opioid characteristics.Design: Post hoc, pooled analysis data from two 12-week, randomized, double-blind, placebo-controlled, phase 3 studies.Setting: Two hundred fifty-seven outpatient centers in the United States Europe.Patients: Patients with noncancer pain...

10.5055/jom.2018.0451 article EN Journal of Opioid Management 2018-07-02

Abstract Collagenase clostridium histolyticum (CCH) is an injectable therapy targeting collagen present in penile plaques Peyronie’s disease (PD). Data comparing CCH to surgery are limited, and long-term therapeutic outcomes unknown. This retrospective analysis used a US claims database (January 2014–June 2017) determine the percentage of men with subsequent among those who initially received ( n = 1227) or (index treatment; 620) for PD. Eligible patients were aged ≥18 years continuous...

10.1038/s41443-021-00522-8 article EN cc-by International Journal of Impotence Research 2022-01-10

Objective: Opioid pain medication continues to be an important treatment option for patients with moderate severe cancer and non-cancer pain; however, limited evidence is available regarding differences in opioid use between these two populations. The objective of this analysis was compare real-world patterns over time populations.Design: Retrospective administrative claims data.Setting: HealthCore Integrated Research Environment database.Patients: Adults ≥1 pharmacy claim (and a confirmed...

10.5055/jom.2019.0481 article EN Journal of Opioid Management 2019-01-01

Memantine is a moderate-affinity, uncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptors, indicated for the treatment moderate to severe Alzheimer's disease (AD). Approved memantine administration 10 mg twice daily (20 mg/day), in form an immediate-release (IR) tablet or solution. In this study, we investigated safety, tolerability, and pharmacokinetics extended-release (ER) capsule (28 mg) healthy volunteers. Phase I, single-center, open-label 16 men 8 women received single oral...

10.1016/j.jalz.2008.05.2474 article EN Alzheimer s & Dementia 2008-07-01

Background: Hypogonadism is characterized by low serum testosterone concentrations and the associated clinical manifestations (e.g., reduced libido, erectile dysfunction, fatigue); therapy (TTh) primary treatment. This study compared treatment patterns health outcomes in men using injection TTh with long-acting undecanoate (TU) versus short-acting cypionate (TC) injection. Methods: A U.S. electronic records (EHR) database was retrospectively reviewed to identify adult who had of TU or TC...

10.1089/andro.2021.0024 article EN cc-by Androgens Clinical Research and Therapeutics 2022-03-01

Gonadotropin-releasing hormone analogs are the treatment of choice for central precocious puberty (CPP). This study characterizes patients treated with histrelin implant or leuprolide injection.A US claims database was used to identify aged ≤20 years ≥1 claim (index treatment) between April 2010 and November 2017 continuous enrollment ≥3 months before ≥12 after index date.Overall, 4,217 (histrelin, n=1,001; leuprolide, n=3,216) were identified. The percentage CPP diagnosis greater in (96.5%)...

10.1515/jpem-2020-0721 article EN cc-by Journal of Pediatric Endocrinology and Metabolism 2021-06-19

Intramuscular testosterone undecanoate is indicated as replacement in adult males with a deficiency or absence of endogenous (hypogonadism). 750 mg approved to be administered at initiation and 4 weeks, followed by maintenance dose every 10 weeks. However, more frequent regimen may improve symptom management low the end each dosing interval. The current objective was develop population pharmacokinetic (PK) model for intramuscular perform PK simulations assess impact an 8-week on exposure. A...

10.1002/jcph.1939 article EN The Journal of Clinical Pharmacology 2021-07-16

10.1016/j.jpainsymman.2015.12.013 article EN publisher-specific-oa Journal of Pain and Symptom Management 2016-01-28
Coming Soon ...